 |
References
American Medical Association (AMA). 1995. Drug Evaluations Annual, 1995. Chicago, Ill.: American Medical Association.
Angell, Marcia. (1997). Science on Trial : The Clash of Medical Evidence and the Law in the Breast Implant Case. New York: W. W. Norton.
Arno, P. S., K. Bonuck, and M. Davis. 1995. Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act. Milbank Quarterly 73, no. 2: 231–52.
Bakke, O. M., M. Manocchia, de F. Abajom, K. Kaitin, and L. Lasagna. 1995. Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective. Clinical Pharmacology and Therapeutics 58, no. 1: 108–17.
Beales, J. Howard, III. 1996. New Uses for Old Drugs. In Competitive Strategies in the Pharmaceutical Industry, edited by R. B. Helms, 281–305. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1997. The Health Consequences of Decisions about Drugs. Unpublished manuscript, George Washington University, Department of Strategic Management and Public Policy.
Bean, William B. 1970. Commentary. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 132–34. Baltimore: Johns Hopkins University Press.
Becker, Gary. 2002. Get the FDA out of the Way, and Drug Prices will Drop. Business Week (Sept. 16, 2002).
Beisler, Joshua H. 2000. Dietary Supplements and Their Discontents: FDA Regulation and the Dietary Supplement Health and Education Act of 1994. Rutgers Law Journal 31: 511–51.
Benham, Lee, and Alexandra Benham. 1975. Regulating through the Professions: A Perspective on Information Control. Journal of Law and Economics 18, no. 2: 421–48.
Brown, Walter A. and B. Severs. 1999. Placebos: Fooling the Body to Heal Itself. USA Today (July) : 32-33.
Burrow, James G. 1970. The Prescription-Drug Policies of the American Medical Association in the Progressive Era. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 112–22. Baltimore: Johns Hopkins University Press.
Calfee, John E. 1996. The Leverage Principle in the FDA’s Regulation of Information. In Competitive Strategies in the Pharmaceutical Industry, edited by R. B. Helms, 306–21. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1997. Fear of Persuasion: A New Perspective on Advertising and Regulation. Monnaz, Switzerland: Agora Association with American Enterprise Institute for Public Policy Research.
Campbell, N. 2000. Exploring Free Market Certification of Medical Devices. In American Health Care: Government, Market Processes and the Public Interest, edited by R. D. Feldman, 313–344. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
CDC. 1999. Infant Metabolic Alkalosis and Soy-Based Formula — United States. MMWR Supplements March 3 1999 / 48(LMRK);121-123.
Conko, G. 1998. A National Survey of Neurologists and Neurosurgeons regarding the Food and Drug Administration. Washington, D.C. Competitive Enterprise Institute, October 5.
Dowling, Harry F. 1970. The American Medical Association’s Policy on Drugs in Recent Decades. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 123–31. Baltimore: Johns Hopkins University Press.
Feldman, Roger D. 2000. American Health Care: Government, Market Processes and the Public Interest. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Gieringer, D. H. 1984. Consumer Choice and FDA Drug Regulation. Ph.D. diss., Department of Engineering-Economic Systems, Stanford University
———. 1985. The Safety and Efficacy of New Drug Approval. Cato Journal 5, no. 1: 177–201.
Grabowski, H. G. 1980. Regulation and the International Diffusion of Pharmaceuticals. In The International Supply of Medicines, edited by R. B. Helms, 5–36. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Grabowski, Henry G., and John M. Vernon. 1983. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington D.C.: American Enterprise Institute for Public Policy Research.
———. 1996. Longer Patents for Increased Generic Competition in the U.S.: The Waxman-Hatch Act after One Decade. PhamacoEconomics 10, no. 2: 110–23.
Grady, Denise. 2001. FDA Pulls a Drug, and Patients Despair. New York Times, 30 January.
Grinspoon, L. 1997. Marihuana, the Forbidden Medicine. 2d ed. New Haven, Conn.: Yale University Press.
Hansen, R. W. 2000. Regulation of the Pharmaceutical Industry. In American Health Care: Government, Market Processes and the Public Interest, edited by R. D. Feldman, 269–84. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Harris, Steven B. 1992. The Right Lesson to Learn from Thalidomide. Available at: http://w3.aces.uiuc.edu:8001/Liberty/Tales/Thalidomide.Html.
Healy, Elaine, and Kenneth Kaitin. 1999. The European Agency for the Evaluation of Medicinal Product’s Centralized Procedure for Product Approval: Current Status. Drug Information Journal 33: 969–78.
Higgs, Robert. 1994. Banning a Risky Product Cannot Improve Any Consumer’s Welfare (Properly Understood), with Applications to FDA Testing Requirements. Review of Austrian Economics 7, no. 2: 3–20.
———, ed. 1995a. Hazardous to Our Health? FDA Regulation of Health Care Products. Oakland, Calif.: The Independent Institute.
———. 1995b. How FDA Is Causing a Technological Exodus: A Comparative Analysis of Medical Device Regulation—United States, Europe, Canada, and Japan. Washington, D.C.: Competitive Enterprise Institute, March.
———. 1995c. FDA Regulation of Medical Devices. In Hazardous to Our Health? FDA Regulation of Health Care Products, edited by Robert Higgs, 55-95. Oakland, Calif.: The Independent Institute.
Holcombe, Randall. 1995. Public Policy and the Quality of Life: Market Incentives versus Government Planning. Westport, CT: Greenwood Press.
Hrobjartsson A. and P. C. Gotzsche. 2001. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine 344:1595-1602.
Ippolito, Pauline M., and Alan D. Mathios. 1990. Information, Advertising, and Health Choices: A Study of the Cereal Market. Rand Journal of Economics 21 (autumn): 459–80.
Kaitin, K. I., and Jeffrey Brown. 1995. A Drug Lag Update. Drug Information Journal 29: 361–73.
Kaitin, K. I., and J. A. DiMasi. 2000. Measuring the Pace of New Drug Development in the User Fee Era. Drug Information Journal 34: 673–80.
Kaitin, K. I., and E. M. Healy. 2000. The New Drug Approvals of 1996, 1997, 1998: Drug Development Trends in the User Fee Era. Drug Information Journal 34: 1–14.
Kaitin, K. I., et al. 1989. The Drug Lag: An Update of New Drug Introductions in the U.S. and U.K., 1977 through 1987. Clinical Pharmacology and Therapeutics 4: 121–38.
Kaplan, Alan H. 1995. Fifty Years of Drug Amendments Revisited: In Easy to Swallow Capsule Form. Food and Drug Law Journal 50 (special issue): 179–96.
Kaplar, Richard T., ed. 1993. Bad Prescription for the First Amendment: FDA Censorship of Drug Advertising and Promotion. Washington, D.C.: Media Institute.
Kazman, S. 1990. Deadly Overcaution. Journal of Regulation and Social Costs 1, no. 1: 35–54.
Keith, Alison. 1995. Regulating Information about Aspirin and the Prevention of Heart Attack. American Economic Review 85 (May): 96–99.
Klein, Daniel B., ed. 1997. Reputation: Studies in the Voluntary Elicitation of Good Conduct. Ann Arbor: University of Michigan Press.
———. 2000a. Assurance and Trust in a Great Society. FEE Occasional Paper No. 2. Irvington, N.Y.: Foundation for Economic Education.
———. 2000b. Policy Medicine Versus Policy Quackery: Economists against the FDA. Knowledge, Technology, and Policy 13 (spring): 92–101.
Kleinfeld, Vincent A. 1970. Commentary and participation in Discussion. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 180–85 and 189–95. Baltimore: Johns Hopkins University Press.
Kohn, Linda T., Janet M. Corrigan, and Molla S. Donaldson, eds. 1999. To Err Is Human: Building a Safer Health System. Washington, D.C.: National Academy Press.
Krauss, Michael I. 1996. Loosening the FDA’s Drug Certification Monopoly: Implications for Tort Law and Consumer Welfare. George Mason Law Review 4 (spring): 457–83.
Lazarou, Jason, et al. 1998. Incidence of Adverse Drug Reactions in Hospitalized Patients. Journal of the American Medical Association 279, no. 15: 1200–1205.
LeBlanc, Stephen, and Rob Sabados. 1996. Oxandrolone Background. Bay Area Reporter, July 11.
Leffler, Keith B. 1981. Persuasion or Information? The Economics of Prescription Drug Advertising. Journal of Law and Economics 24, 1: 45-74.
Libecap, Gary D. 1992. The Rise of the Chicago Packers, and the Origins of Meat Inspection and Antitrust. NBER Historical Working Paper No. 29. Economic Inquiry (April 1992): 242–62.
Masson, Alison, and Paul H. Rubin. 1985. Matching Prescription Drugs and Consumers. New England Journal of Medicine 313 (August 22): 513–15.
Meyers, A. S. 1991. The U.S. Orphan Drug Act: Should the Law Cover Highly Profitable Drugs? World Pharmaceutical Standards Review 1: 24–25.
Miller, Henry I. 1998. Failed FDA Reform. Regulation 21, no. 3: 24–30.
———. 2000. To America's Health: A Proposal to Reform the Food and Drug Administration. Stanford, Calif.: Hoover Institution Press.
Moore, Thomas J. 1995. Deadly Medicine. New York: Simon and Schuster.
Munsey, Rodney R. 1995. Medical Device Regulation. Food and Drug Law Journal 50 (special issue): 163–177.
Parkinson, Thomas L. 1975. The Role of Seals and Certifications of Approval in Consumer Decision-Making. Journal of Consumer Affairs 9 (summer): 1–14.
Pasour, E. C., Jr. 1998. We Can Better Than Government Inspection of Meat. The Freeman (May 1998).
Pearson, Durk, and Sandy Shaw. 1993. Freedom of Informed Choice: FDA Versus Nutrient Supplements. Neptune, N.J.: Common Sense.
———. 1999. FDA TKO. Liberty (April): 27–29.
Peltzman, S. 1973. An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. Journal of Political Economy 81, no. 5: 1049–91. Reprinted in Chicago Studies in Political Economy, edited by George J. Stigler, 303–48. Chicago, University of Chicago Press, 1988.
———. 1974. Regulation of Pharmaceutical Innovation: The 1962 Amendments. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1987. The Health Effects of Mandatory Prescriptions. Journal of Law and Economics 30, no. 2: 207–38.
Pinco, R. G., and P. D. Rubin. 1996. Ambiguities of the Dietary Supplement Health and Education Act of 1994. Food and Drug Law Journal 51: 383–405.
Ross, M.F. 1996. FDA Proposes Labelling Aspirin for Use at Onset of Heart Attack. University of Florida, News and Public Affairs Press Release (June 14).
Rothenberg, Jerome. 1993. Social Strategy and the Tactics in the Search for Safety. Critical Review 7: 159–80.
Rubin, Paul H. 1991a. Economics of Prescription Drug Advertising. Journal of Research in Pharmaceutical Economics 3: 29–41.
———. 1991b. The Economics of Regulating Deception. Cato Journal 10: 667–90.
———. 1994. Are Pharmaceutical Ads Deceptive? Food and Drug Law Journal 49: 7–19.
———. 1995. FDA Advertising Restrictions: Ignorance Is Death. In Hazardous to Our Health? FDA Regulation of Health Care Products, edited by Robert Higgs, 29–53. Oakland, Calif.: The Independent Institute.
———. 2004. An Opportunity Or a Threat: How to Have Safer, Less Expensive Drugs. The Independent Institute, December 7, 2004.
Sobel, Russell S. 2002 Public Health and the Placebo: The Legacy of the 1906 Pure Food and Drug Act. Cato Journal 21 (3), Winter: 463-79.
Sonnedecker, Glenn. 1970. Contribution of the Pharmaceutical Profession toward Controlling the Quality of Drugs in the Nineteenth Century. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 97–111. Baltimore: Johns Hopkins University Press.
Starr, Paul. 1982. The Social Transformation of American Medicine. New York: Basic.
Statman, Meir. 1983. Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Tabarrok, Alexander. 2000. Assessing the FDA via the Anomaly of Off-Label Drug Prescribing. The Independent Review 5, no. 1: 25–53.
Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, Mass.: Harvard University Press.
———. 1992. Realized Benefits from Switching Drugs. Journal of Law and Economics 35: 351–69.
Thomas, L. G. 1990. Regulation and Firm Size: FDA Impacts on Innovation. Rand Journal of Economics 21, no. 4: 497–517.
Tollison, Robert. 1996. Institutional Alternatives for the Regulation of Drugs and Medical Devices. In Advancing Medical Innovation: Health, Safety, and the Role of Government in the 21st Century, edited by Ralph Epstein, 17-40. Washington, D.C.: Progress and Freedom Foundation.
Viscusi, W. Kip. 1996. "Regulatory Reform and Liability for Pharmaceuticals and Medical Devices," Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century, The Progress and Freedom Foundation, February 7, 1996: 79-102.
Volokh, Alexander. 1995. Clinical Trials: Beating the FDA in Court. Reason (May).
———. 1997. Software Pirates. Reason (November).
Wardell, W. M. 1973. Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison. Clinical Pharmacology and Therapeutics 14, no. 5: 773–90.
———. 1978a. A Close Inspection of the “Calm Look.” Journal of the American Medical Association 239, no. 19: 2004–11.
———. 1978b. The Drug Lag Revisited: Comparisons by Therapeutic Area of Patterns of Drugs Marketed in the U.S. and Great Britain from 1972 through 1976. Clinical Pharmacology and Therapeutics 24: 499–524.
Wardell, W. M., and L. Lasagna. 1975. Regulation and Drug Development. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Weidenbaum, Murray. 1993. Are Drug Prices Too High? The Public Interest (summer): 84–89.
Weimer, David Leo. 1982. Safe—and Available—Drugs. In Instead of Regulation: Alternatives to Federal Regulatory Agencies, edited by R. W. Poole, 239–83. Lexington, Mass.: D. C. Heath.
Wiggins, S. N. 1981. Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s. Review of Economics and Statistics 63: 615–19.
Wildavsky, Aaron. 1988. Searching for Safety. New Brunswick, N.J.: Transaction Publishers.
———. 2000. Regulation of Carcinogens: Are Animal Tests a Sound Foundation? In Cutting Green Tape: Toxic Pollutants, Environmental Regulation and the Law, edited by R. L. Stroup and R. E. Meiners, 251–80. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Willman, David. 2000. How a New Policy Led to Seven Deadly Drugs. Los Angeles Times, Dec. 20.
Woelk, H. 2000. Comparison of St. John’s Wort and Imipramine for Treating Depression: Randomised Controlled Trial. British Medical Journal 321: 536–39.
Young, James Harvey. 1970. Drugs and the 1906 Law. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 147–57. Baltimore: Johns Hopkins University Press.
Click Here for Additional Health Care References from The Independent Institute.
|
